Project Details
Description
Commercialization of selective Dyrk1a inhibitors for Down syndrome Commercialization of selective Dyrk1a inhibitors for Down syndrome
| Status | Active |
|---|---|
| Effective start/end date | 10/1/22 → 9/30/23 |
Funding
- HHS: National Institutes of Health (NIH): $185,965.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.